Resources Repository
-
BookPublication 2013Making Hard Decisions with Decision Tools, 3rd Edition
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas …
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas of decision analysis, without an overly technical explanation of the mathematics used in decision analysis. This new version has been purposefully written to be more relevant to students in business and engineering compared to previous versions. This new version also incorporates and implements the powerful DecisionTools® software by Palisade Corporation. At the end of each chapter, topics are illustrated with step-by-step instructions…
Probability/Bayes | Value of Information | North America | Policy/Regulation | Preferences/Values | Test Performance | Microsimulation | Decision Analysis | Business/Industry | Energy/Engineering | Health/Medicine | Military/Defense | Science/Technology | Global | Europe -
BookPublication 2010Problem Solving, Decision Making, and Professional Judgment
This book includes material drawn from statistics, decision science, social and cognitive psychology, the judgment …
This book includes material drawn from statistics, decision science, social and cognitive psychology, the judgment and decision making literature, and behavioral economics. It combines quantitative approaches to empirical analysis and decision making (i.e., statistics and decision science) with the psychological literature illustrating the systematic errors of the intuitive decision maker.
Probability/Bayes | Value of Information | North America | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Test Performance | Decision Analysis | Cost-Effectiveness Analysis | Government/Law | Health/Medicine | Global -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Costing Methods | Value of Information | North America | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Value of Information | North America | Policy/Regulation | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Economics/Finance | Europe -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Probability/Bayes | North America | Policy/Regulation | Test Performance | Technology Assessment | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | Global -
Resource PackPublication, Teaching Resource 2022Resource Pack: Decision Analysis & Childhood Obesity
This resource pack on childhood obesity was curated by the Center for Health Decision Science …
This resource pack on childhood obesity was curated by the Center for Health Decision Science to showcase existing cost-effectiveness analyses and motivate students, educators, and others to pursue new applications of decision science methods to the public health challenge of obesity. The resource pack was motivated by the NEJM article entitled Simulation of Growth Trajectories of Childhood Obesity into Adulthood published on November 30, 2017, with CHDS co-authors Zach Ward and Stephen Resch. Citation: Ward Z, Long M,…
Costing Methods | North America | Policy/Regulation | Health Outcomes | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Clinical Care | Culture/Society | Economics/Finance | Food/Agriculture | Health/Medicine -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Costing Methods | North America | Policy/Regulation | Preferences/Values | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Costing Methods | North America | Policy/Regulation | Benefit-Cost Analysis | Chronic Disease/Risk | Government/Law | Health/Medicine -
DataWeb Portal 2024Medical Expenditure Panel Survey (MEPS)
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring …
The Medical Expenditure Panel Survey (MEPS) is the only national data source in the U.S. measuring how Americans use and pay for medical care, health insurance, and out-of-pocket spending. Annual surveys of individuals and families, as well as their health care providers, provide data on health status, the use of medical services, charges, insurance coverage, and satisfaction with care. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form…
Costing Methods | North America | Policy/Regulation | Health Outcomes | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine